Johnson & Johnson posted a 6.5% year-over-year increase in sales of its Stelara (ustekinumab) treatment for pediatric patients with juvenile psoriatic arthritis in 2022, to
Tagrisso ranked # 1 among AstraZeneca’s top medicines by the amount of its sales in 2020. Sales of this drug totaled $ 4.328 million last
Johnson & Johnson posted a 6.5% year-over-year increase in sales of its Stelara (ustekinumab) treatment for pediatric patients with juvenile psoriatic arthritis in 2022, to
Tagrisso ranked # 1 among AstraZeneca’s top medicines by the amount of its sales in 2020. Sales of this drug totaled $ 4.328 million last
